*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Aaron Rosado
BME PhD Proposal Presenation
Date: December 3rd, 2018
Time: 1:00pm
Location: McIntire Room
Advisor: Cheng Zhu
Committee Members:
Arash Grakoui (Emory)
Susan Thomas (BME)
Michael Davis (BME)
Michelle Krogsgaard (NYU)
Title: Impairment of Mechanosensing and Lateral Crosstalk Among Immune Receptors in Tumor Infiltrating Lymphocytes
Abstract/Summary:
The tumor microenvironment’s (TME) unique immune characteristics play a major role in shaping tumor immune responses. Immune cells infiltrating into the tumor microenvironment encounter unique microenvironmental cues potentially resulting in anti-tumor immune response suppression. Immune checkpoint blockade (ICB) attempts to suppress inhibitory immune checkpoint receptors in ways that enhance anti-tumor immunity. Although ICB clearly enhances cytotoxic potential in infiltrating cytotoxic T cells, many questions remain about immune checkpoint receptors function within the TME. We propose that the TME impairs infiltrating cytotoxic T cell CD8, CD28, CTLA-4, and TCR complex mechanosensing and lateral crosstalk (LC). We will investigate TME immune synapse receptor mechanosensing and LC impairment in infiltrating cytotoxic T cells with bond quality and quantity measurements. We will employ biomechanical switching instrument techniques towards controlling LC spatially and temporally. We will demonstrate immune synapse receptor mechanosensing and LC impairment functionally impairs T cell function and can be modulated with small molecule inhibitors. We believe investigations into mechanosensing and LC impairment will provide invaluable immune checkpoint signaling insights and motivate cancer immunotherapy improvements.
